Upper Tract Urothelial Carcinoma VL

Upper Tract Urothelial Carcinoma - Clinical Case Management in High-Risk Disease - Sima Porten

Details
In this patient case evaluation discussion, Sima Porten joins Sam Chang presenting a case of a 64-year-old man with high-risk urothelial carcinoma. He presented with gross hematuria. His workup initially was started with a cystoscopy that was done by a urologist close to home, which was normal. Biographies: Sima P. Porten, MD, MPH, Assistant Professor, Department of Urology, UCSF Medical Center Sa...

Risk Stratification of Upper Tract Urothelial Carcinoma - Doug Scherr

Details
Sam Chang and Doug Scherr discuss risk stratification for patients with upper urinary tract cancer (UTUC). They discuss cancer recurrences and how it may be possible to predict the likelihood of these events. They evaluate tumor-specific factors and treatment-specific factors. Dr. Scherr discusses the future of prognostic genomic risk scores for upper tract urothelial carcinoma, similar to those a...

Genetics in Upper Tract Urothelial Cancer, What Urologists Should Know – Eugene J. Pietzak

Details
Eugene Pietzak details the molecular landscape of upper tract urothelial carcinoma and highlights practical clinical implications of recent findings of the molecular biology of upper tract urothelial cancer, with a particular focus on what is relevant to the urologist in this conversation with Sam Chang. Upper tract urothelial cancer comprises a very small proportion of all urothelial cancer. it h...

Management and Challenges of Low Grade Upper Tract Urothelial Carcinoma - Surena Matin

Details
In this patient case evaluation discussion, Surena Matin joins Sam Change presenting a patient case of low grade, upper tract, urothelial cancer. This was a 71-year-old patient who presented with microhematuria and he was found to have a 7 mm lesion in the distal, right ureter. Drs. Matin and Chang discuss diagnosing and staging the patient, and Dr. Matin talks through his approach to treatment. G...

Treatment Considerations for Upper Tract Urothelial Carcinoma - Eugene Pietzak and Arjun Balar

Details
Upper tract urothelial (transitional cell) carcinoma (UTUC) is a rare malignant disease occurring in roughly two people per 100 000 population. UTUCs comprise 5–10% of urothelial carcinomas. Given limited high-level evidence, Dr. Chang brings together two experts to discuss their approaches in various clinical scenarios. Sam Chang, MD hosts experts Eugene Pietzak, urologist, and Arjun Balar, medic...

How I Use Jelmyto™ - Karim Chamie

Details
In April 2020, the US Food and Drug Administration approved Jelmyto (mitomycin gel) as the first therapy for low-grade UTUC. One year later, Jelmyto has become a valuable treatment that urologists can incorporate into their clinical armamentarium. In this conversation with Sam Chang, Karim Chamie provides a state-of-the-art lecture on UTUC and treatment in 2021. Dr. Chamie summarizes risk stratifi...

Upper Tract Urothelial Carcinoma - Clinical Case Management – Jonathan Coleman

Details
Jonathan Coleman joins Sam Chang for a case-based clinical conversation on the management of upper tract urothelial carcinoma (UTUC). Dr. Coleman presents a case of a 71-year-old woman with microhematuria. Her CT scan identified a mass in the right renal pelvis and her cystoscopy was unremarkable. Dr. Coleman talks through the steps that were taken in the management of this case, which involved a...

Primary Chemoablation for the Treatment of Low-Grade Upper Tract Urothelial Carcinoma: The OLYMPUS Trial - Seth Lerner

Details
Seth Lerner, MD, FACS, presents updated information on the United States Federal Drug Administration (FDA) approval of Jelmyto (UGN-101) for low-grade upper tract urothelial carcinoma (LG-UTUC), and the results of the OLYMPUS trial, Optimized DeLivery of Mitomycin for Primary UTUC Study (Olympus) . LG-UTUC is rare and previously there were few kidney-sparing options. UGN-101 is a mixture of a ther...

Lancet Oncology OLYMPUS Trial Review: Primary Chemoablation for the Treatment of Low Grade Upper Tract Urothelial Carcinoma

Details
Seth Lerner and Sam Change discuss the recent phase 3 OLYMPUS study, published in The Lancet Oncology. Dr. Lerner was the principal investigator of the single-arm study which investigated the use of thermal-reversible gel mitomycin (Jelmyto) for low-grade upper tract urothelial cancer (UTUC). The study had a 59% complete response rate and thus identified and the FDA approved Jelmyto as a kidney-sp...

Developments in Treatment Options for Localized and Advanced Upper Tract Disease - Vitaly Margulis

Details
Vitaly Margulis joins Ashish Kamat in a discussion on the top three developments in upper tract urothelial treatment starting with localized disease and moving onto the more advanced disease. With the difficulty in administering treatment in the upper tract, Dr. Margulis highlights intracavitary therapies, genetic changes that are prevalent in upper tract advanced disease, and the use of systemic...
email news signup